Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

AMG 986 is a first-in-class, novel apelin receptor small molecule agonist initially developed for the treatment of heart failure (HF). The safety and pharmacokinetics (PK) of AMG 986 in participants with renal impairment (RI) remains unknown. This phase 1 study compared the safety and PK of AMG 986 200 mg in six participants with severe RI (estimated glomerular filtration rate [eGFR] 15-29 mL/min/1.73 m2) versus six participants with normal renal function (eGFR ≥ 90 mL/min/1.73 m2). Following a single oral dose of AMG 986 200 mg on day 1, the maximum observed concentration increased 1.41-fold (90% confidence interval [CI] 0.88-2.27) and the area under the curve from time zero to infinity increased 1.23-fold (90% CI 0.73-2.06) in participants with severe RI versus normal renal function. AMG 986 had an acceptable safety profile; all adverse events were mild in severity. The results of this study support the enrollment of HF patients with RI to clinical trials of AMG 986 without the need for dose adjustments. NCT03318809 (registered: October 24, 2017). © 2022. The Author(s).


Ashit Trivedi, Omar Mather, Silvia Vega, Mary Ann Simiens, Jennifer Hellawell, Edward Lee. Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986. Drugs in R&D. 2022 Mar;22(1):89-94

Expand section icon Mesh Tags

PMID: 35092583

View Full Text